Company intelligence / Profile preview

ArcoScreen

Lausanne, Vaud, Switzerland

Ownership: Private
Development stage: Preclinical

Overview

ArcoScreen has developed and commercialized a patented microfluidic chip assay platform ("ArcoFlow") that enables rapid and accurate identification of drugs targeting GPCRs directly on primary patient cells. This approach allows pharmaceutical companies to predict drug efficacy earlier in the discovery process—before expensive clinical trials—by testing compounds in physiologically relevant systems. The company’s technology is designed to improve the success rate of drug development by providing more predictive preclinical data.

Therapeutic areas: Other
Modalities: Small moleculePeptidesBiologic (including monoclonal antibodies and other biologics)
Industry: Drug Discovery Services

Partnerships

No specific major pharma/biotech partnerships disclosed in public sources as of June 2025.

Beyond the preview

Go deeper on ArcoScreen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArcoScreen.

Explore the full profile